

ABSTRACT OF THE DISCLOSURE

The invention relates to the use of a central cannabinoid receptor antagonist, by itself or in association with a compound for regulating metabolic disorders, especially a  $\beta_3$ -adrenergic receptor agonist, for the preparation of drugs useful in the treatment of appetency disorders.